Selected research
Industry Research
Cancer Pain Therapeutics Industry Research Report 2026
Market perspective
The global Cancer Pain Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cancer Pain Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cancer Pain Therapeutics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cancer Pain Therapeutics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cancer Pain Therapeutics include BioDelivery Science, Grunenthal Group, GW Pharmaceuticals, Meda Pharmaceuticals, Orexo, ProStrakan Group, WEX Pharmaceuticals, Eli-Lilly and Johnson＆Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cancer Pain Therapeutics market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cancer Pain Therapeutics Market by Company
BioDelivery Science
Grunenthal Group
GW Pharmaceuticals
Meda Pharmaceuticals
Orexo
ProStrakan Group
WEX Pharmaceuticals
Eli-Lilly
Johnson＆Johnson
Sanofi
Teva pharmaceuticals
Cancer Pain Therapeutics Segment by Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
Cancer Pain Therapeutics Segment by Application
Hormone Therapy
Chemotherapy
Radiotherapy
Paracetamol Treatment-Related Immunotherapy
Cancer Pain Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Pain Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Pain Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Pain Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cancer Pain Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cancer Pain Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cancer Pain Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Opioids
- Non-Steroidal Anti-Inflammatory Drugs
- Others
Applications
- Hormone Therapy
- Chemotherapy
- Radiotherapy
- Paracetamol Treatment-Related Immunotherapy
Companies covered
- BioDelivery Science
- Grunenthal Group
- GW Pharmaceuticals
- Meda Pharmaceuticals
- Orexo
- ProStrakan Group
- WEX Pharmaceuticals
- Eli-Lilly
- Johnson＆Johnson
- Sanofi
- Teva pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cancer Pain Therapeutics Market Size (2021-2032)
- 2.2.2 Global Cancer Pain Therapeutics Sales (2021-2032)
- 2.2.3 Global Cancer Pain Therapeutics Market Average Price (2021-2032)
- 2.3 Cancer Pain Therapeutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Opioids
- 2.3.3 Non-Steroidal Anti-Inflammatory Drugs
- 2.3.4 Others
- 2.4 Cancer Pain Therapeutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hormone Therapy
- 2.4.3 Chemotherapy
- 2.4.4 Radiotherapy
- 2.4.5 Paracetamol Treatment-Related Immunotherapy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cancer Pain Therapeutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cancer Pain Therapeutics Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Cancer Pain Therapeutics Revenue of Manufacturers (2021-2026)
- 3.4 Global Cancer Pain Therapeutics Average Price by Manufacturers (2021-2026)
- 3.5 Global Cancer Pain Therapeutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cancer Pain Therapeutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cancer Pain Therapeutics, Product Type & Application
- 3.8 Global Manufacturers of Cancer Pain Therapeutics, Established Date
- 3.9 Global Cancer Pain Therapeutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 BioDelivery Science
- 4.1.1 BioDelivery Science Company Information
- 4.1.2 BioDelivery Science Business Overview
- 4.1.3 BioDelivery Science Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 BioDelivery Science Cancer Pain Therapeutics Product Portfolio
- 4.1.5 BioDelivery Science Recent Developments
- 4.2 Grunenthal Group
- 4.2.1 Grunenthal Group Company Information
- 4.2.2 Grunenthal Group Business Overview
- 4.2.3 Grunenthal Group Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Grunenthal Group Cancer Pain Therapeutics Product Portfolio
- 4.2.5 Grunenthal Group Recent Developments
- 4.3 GW Pharmaceuticals
- 4.3.1 GW Pharmaceuticals Company Information
- 4.3.2 GW Pharmaceuticals Business Overview
- 4.3.3 GW Pharmaceuticals Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GW Pharmaceuticals Cancer Pain Therapeutics Product Portfolio
- 4.3.5 GW Pharmaceuticals Recent Developments
- 4.4 Meda Pharmaceuticals
- 4.4.1 Meda Pharmaceuticals Company Information
- 4.4.2 Meda Pharmaceuticals Business Overview
- 4.4.3 Meda Pharmaceuticals Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Meda Pharmaceuticals Cancer Pain Therapeutics Product Portfolio
- 4.4.5 Meda Pharmaceuticals Recent Developments
- 4.5 Orexo
- 4.5.1 Orexo Company Information
- 4.5.2 Orexo Business Overview
- 4.5.3 Orexo Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Orexo Cancer Pain Therapeutics Product Portfolio
- 4.5.5 Orexo Recent Developments
- 4.6 ProStrakan Group
- 4.6.1 ProStrakan Group Company Information
- 4.6.2 ProStrakan Group Business Overview
- 4.6.3 ProStrakan Group Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 ProStrakan Group Cancer Pain Therapeutics Product Portfolio
- 4.6.5 ProStrakan Group Recent Developments
- 4.7 WEX Pharmaceuticals
- 4.7.1 WEX Pharmaceuticals Company Information
- 4.7.2 WEX Pharmaceuticals Business Overview
- 4.7.3 WEX Pharmaceuticals Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 WEX Pharmaceuticals Cancer Pain Therapeutics Product Portfolio
- 4.7.5 WEX Pharmaceuticals Recent Developments
- 4.8 Eli-Lilly
- 4.8.1 Eli-Lilly Company Information
- 4.8.2 Eli-Lilly Business Overview
- 4.8.3 Eli-Lilly Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli-Lilly Cancer Pain Therapeutics Product Portfolio
- 4.8.5 Eli-Lilly Recent Developments
- 4.9 Johnson＆Johnson
- 4.9.1 Johnson＆Johnson Company Information
- 4.9.2 Johnson＆Johnson Business Overview
- 4.9.3 Johnson＆Johnson Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Johnson＆Johnson Cancer Pain Therapeutics Product Portfolio
- 4.9.5 Johnson＆Johnson Recent Developments
- 4.10 Sanofi
- 4.10.1 Sanofi Company Information
- 4.10.2 Sanofi Business Overview
- 4.10.3 Sanofi Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sanofi Cancer Pain Therapeutics Product Portfolio
- 4.10.5 Sanofi Recent Developments
- 4.11 Teva pharmaceuticals
- 4.11.1 Teva pharmaceuticals Company Information
- 4.11.2 Teva pharmaceuticals Business Overview
- 4.11.3 Teva pharmaceuticals Cancer Pain Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Teva pharmaceuticals Cancer Pain Therapeutics Product Portfolio
- 4.11.5 Teva pharmaceuticals Recent Developments
5 Global Cancer Pain Therapeutics Market Scenario by Region
- 5.1 Global Cancer Pain Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cancer Pain Therapeutics Sales by Region: 2021-2032
- 5.2.1 Global Cancer Pain Therapeutics Sales by Region: 2021-2026
- 5.2.2 Global Cancer Pain Therapeutics Sales by Region: 2027-2032
- 5.3 Global Cancer Pain Therapeutics Revenue by Region: 2021-2032
- 5.3.1 Global Cancer Pain Therapeutics Revenue by Region: 2021-2026
- 5.3.2 Global Cancer Pain Therapeutics Revenue by Region: 2027-2032
- 5.4 North America Cancer Pain Therapeutics Market Facts & Figures by Country
- 5.4.1 North America Cancer Pain Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cancer Pain Therapeutics Sales by Country (2021-2032)
- 5.4.3 North America Cancer Pain Therapeutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cancer Pain Therapeutics Market Facts & Figures by Country
- 5.5.1 Europe Cancer Pain Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cancer Pain Therapeutics Sales by Country (2021-2032)
- 5.5.3 Europe Cancer Pain Therapeutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cancer Pain Therapeutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cancer Pain Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cancer Pain Therapeutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cancer Pain Therapeutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cancer Pain Therapeutics Market Facts & Figures by Country
- 5.7.1 South America Cancer Pain Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cancer Pain Therapeutics Sales by Country (2021-2032)
- 5.7.3 South America Cancer Pain Therapeutics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cancer Pain Therapeutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cancer Pain Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cancer Pain Therapeutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cancer Pain Therapeutics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cancer Pain Therapeutics Sales by Type (2021-2032)
- 6.1.1 Global Cancer Pain Therapeutics Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Cancer Pain Therapeutics Sales Market Share by Type (2021-2032)
- 6.2 Global Cancer Pain Therapeutics Revenue by Type (2021-2032)
- 6.2.1 Global Cancer Pain Therapeutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cancer Pain Therapeutics Revenue Market Share by Type (2021-2032)
- 6.3 Global Cancer Pain Therapeutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cancer Pain Therapeutics Sales by Application (2021-2032)
- 7.1.1 Global Cancer Pain Therapeutics Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Cancer Pain Therapeutics Sales Market Share by Application (2021-2032)
- 7.2 Global Cancer Pain Therapeutics Revenue by Application (2021-2032)
- 7.2.1 Global Cancer Pain Therapeutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cancer Pain Therapeutics Revenue Market Share by Application (2021-2032)
- 7.3 Global Cancer Pain Therapeutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cancer Pain Therapeutics Value Chain Analysis
- 8.1.1 Cancer Pain Therapeutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cancer Pain Therapeutics Production Mode & Process
- 8.2 Cancer Pain Therapeutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cancer Pain Therapeutics Distributors
- 8.2.3 Cancer Pain Therapeutics Customers
9 Global Cancer Pain Therapeutics Analyzing Market Dynamics
- 9.1 Cancer Pain Therapeutics Industry Trends
- 9.2 Cancer Pain Therapeutics Industry Drivers
- 9.3 Cancer Pain Therapeutics Industry Opportunities and Challenges
- 9.4 Cancer Pain Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst